Arrowhead Pharmaceuticals, Inc. (ARWR) Market Cap & Valuation Ratios
Arrowhead Pharmaceuticals, Inc. (ARWR) has a market cap of $8.2B and a price-to-sales ratio of 12.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ARWRArrowhead Pharmaceuticals, Inc.Follow ARWR — free
—
Price chart with a free account
- Market cap
- 8.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 23 Nov, in 30 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| ARWR | 8.2 | — | 11.1 | — | -0.9% | +17% | -34% | -24% |
| KRYS | 9.2 | 39.0 | 19.0 | 41.1 | 2.8% | +23% | 45% | 19% |
| KYMR | 9.2 | — | 81.1 | — | -2.6% | +135% | -334% | -35% |
| CAI | 9.0 | 85.6 | 8.7 | 49.7 | 1.4% | +85% | 15% | 61% |
| PCVX | 9.0 | — | — | — | -10.2% | — | — | -44% |
| PTGX | 9.0 | 135.7 | 29.0 | 136.5 | 1.5% | +35% | 21% | 12% |
| IBRX | 8.7 | — | 57.6 | — | -3.3% | +193% | -152% | -319% |
| CYTK | 8.5 | — | 125.5 | — | -6.8% | -21% | — | -99% |
| TGTX | 8.3 | 19.7 | 10.6 | 62.2 | 0.2% | +76% | 17% | 17% |
| SYRE | 8.0 | — | — | — | -2.6% | — | — | -31% |
| AXSM | 7.6 | — | 9.6 | — | -0.9% | +57% | -24% | — |
| Median of these 10 | 62.3 | 24.0 | 55.9 | -1.8% | +66% | 15% | -31% |
; EV/Sales 11.1 vs. 24.0.
Growth vs. price
each dot a company · hover or tap for valuesARWR and KYMR and PCVX and IBRX and CYTK and SYRE and AXSM have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Arrowhead Pharmaceuticals, Inc. — questions
- What is Arrowhead Pharmaceuticals, Inc.'s market cap?
- $8.2B.
- What is Arrowhead Pharmaceuticals, Inc.'s price-to-sales ratio?
- 12.2.
Every figure on this page comes from Arrowhead Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.